Antibiotic

For treatment and control of SRD and control of Colibacillosis

Target seven bacterial pathogens with a single injection

Enrofloxacin, the active ingredient in Tenotryl™  injectable solution is an efficient, broad-spectrum antibiotic that has been trusted in the U.S. swine industry for 25 years. A convenient, single-dose injection delivers swift and broad action against seven bacterial pathogens that cause swine respiratory disease (SRD), as well as colibacillosis associated with E. coli.

Tenotryl_Swine_chart_72dpi.jpg

Tenotryl_Swine_pig_dose_banner4.jpg

Familiar dosing

Tenotryl™ injectable solution has a convenient single dose in the same enrofloxacin dosage schedule you’re familiar with. U.S. federal law restricts this drug to use by or on the order of a licensed veterinarian and prohibits the extra-label use of this drug in food producing animals. To assure responsible antimicrobial drug use, enrofloxacin should only be used as a second-line drug for colibacillosis in swine following consideration of other therapeutic options.

Tenotryl_Swine_dosing_triangle.jpg

Tenotryl_Swine_dosing.jpg

 

Kills key bacterial SRD pathogens and E. Coli

Tenotryl™ injectable solution possesses the activity needed to kill most of the primary SRD pathogens and E. coli. Enrofloxacin is a broad-spectrum antibiotic with low minimal inhibitory concentration (MIC) on the primary agents of SRD and colibacillosis associated with E. coli. Its bactericidal effects are concentration or time dependent.1

The effects of enrofloxacin on swine reproductive performance, pregnancy and lactation have not been adequately determined. The long-term effects on articular joint cartilage have not been determined in pigs above market weight.

Tenotryl_Swine_para_chart.jpg

 

Reliable, single-dose therapy to provide convenient and comprehensive clinical benefits for key pathogens associated with SRD and colibacillosis.
 

Interstitial fluid pharmacokinetic parameters
from enrofloxicin injection at 7.5 mg/kg body weight4

Tenotryl_Swine_para_weight_2.jpg

 

Tenotryl_Swine_graphic.jpg

Indications:

TenotrylTM (enrofloxacin) injectable solution is indicated for the treatment of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Haemophilus parasuis, Streptococcus suis, Bordetella bronchiseptica and Mycoplasma hyopneumoniae. It is also indicated for the control of colibacillosis in groups or pens of weaned pigs where colibacillosis associated with Escherichia coli has been diagnosed. To assure responsible antimicrobial drug use, enrofloxacin should only be used as a second-line drug for colibacillosis in swine following consideration of other therapeutic options.

 

Tenotryl™ is marketed in the U.S. by Pharmgate Animal Health. Talk to your Pharmgate representative or visit pharmgate.com/tenotryl.

 

SWINE IMPORTANT SAFETY INFORMATION
TenotrylTM (enrofloxacin) 100 mg/ml Antimicrobial Injectable Solution:
Not for use in humans. For intramuscular or subcutaneous use in swine. Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian and prohibits the extra-label use of this drug in food producing animals. To assure responsible antimicrobial drug use, enrofloxacin should only be used as a second-line drug for colibacillosis in swine following consideration of other therapeutic options. Animals intended for human consumption must not be slaughtered within 5 days of receiving a single injection dose. The effects of enrofloxacin on swine reproductive performance, pregnancy and lactation have not been adequately determined. The long-term effects on articular joint cartilage have not been determined in pigs above market weight. Subcutaneous or intramuscular injection in swine can cause a transient local tissue reaction and may result in trim loss of edible tissue at slaughter. Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders.

 

TENOTRYL is a trademark of Virbac S.A.

Need more information?

Contact form

References

  1. Giguére, S.; Prescot, J.F.; Dowling, P.M. 2013. Antimicrobial Therapy in Veterinary Medicine, Fifth Edition.
  2. Shivdeep SH, et al. 2020 Prevalence and time trend analysis of antimicrobial resistance in respiratory bacterial pathogens collected from diseased pigs in USA between 2006-2016. Research in Veterinary Science. 128:135-144.
  3. Assunçao P, et al. 2007. Application of flow cytometry for the determination of minimal inhibitory concentration of several antibacterial agents on Mycoplasma hyopneumoniae, J Appl. Microbiol. 102:1132–1137.
  4. Messenger, K.M. et al. 2011. Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin in pigs. J. vet. Pharmacol. Therap. doi: 10.1111/j.1365-2885.2011.01338.x.